Floatz logo

Nadolol

Migraine Disorder

Ohio UniversitySmall moleculePhase 4 / ApprovedDormant
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

101 Active assets in the Migraine Disorder cohort.

Asset / SponsorPhaseRating
Atogepant
Stanford University
Phase 4A
Naproxen
IRCCS San Raffaele Roma
Phase 4A
Zolmitriptan
Zosano Pharma Corporation
Phase 4A
Rizatriptan
Antonios Likourezos
Phase 4A
Eptinezumab
Stanford University
Phase 4BBB

View all 50 →

Same molecule, other indications

Nadolol is also rated in:

esophageal varices with bleedingDormant
BB
Indicative · Phase 4
69 / 100
View asset →
portal hypertensionDormant
BB
Indicative · Phase 4
65 / 100
View asset →
cirrhosis of liverDormant
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →